Welcome to the Stocktwits Top 25 Newsletter this week!

The Stocktwits Top 25 reports the 25 best-performing stocks in the S&P 500, Nasdaq 100, and Russell 2000 year to date and tracks their performances over time. To help you understand this data further, check out our FAQ page, and feel free to reach out if you have questions!

Bearish 🐻 | Bullish 🐮 | It’s Complicated 😵‍💫

Here are the Stocktwits Top 25 Lists for this week:

If you work in fintech or finance, you already have too many tabs open and not enough time.

Fintech Takes is the free newsletter senior leaders actually read. Each week, I break down the trends, deals, and regulatory moves shaping the industry — and explain why they matter — in plain English.

No filler, no PR spin, and no “insights” you already saw on LinkedIn eight times this week. Just clear analysis and the occasional bad joke to make it go down easier.

Get context you can actually use. Subscribe free and see what’s coming before everyone else.

Sign Up Free

Rank gains hid a rough week: several leaders climbed because other stocks fell harder, while CareDx delivered an actual breakout.

$ATEX ( ▼ 1.24% ) : Anterix, Russell 2000 #23 → #7: Shares slipped -1.2% for the week despite jumping 16 spots. The utility-network spectrum owner heads into November 10 results with newly announced iPhone compatibility expanding its device ecosystem. Risk: Device support still needs to translate into utility contracts and spectrum revenue.

$IBRX ( ▼ 5.15% ) : ImmunityBio, Russell 2000 #17 → #6: The stock fell -5.1%, but November brings a concrete catalyst: the company expects bladder-cancer trial results for Anktiva plus BCG in previously untreated patients. Risk: Those results remain binary, and the planned fourth-quarter filing depends on the data supporting expansion.

$CDNA ( ▲ 22.22% ) : CareDx, Russell 2000 new at #3: Shares jumped +22.2% for the week. Reuters reported quarterly revenue of $139.4M versus $120.6M expected, alongside higher annual guidance. Risk: Testing revenue included $15M from prior periods, making the headline growth rate harder to repeat.

$AGL ( ▼ 1.21% ) : agilon health, Russell 2000 #5 → #1: A -1.2% week still carried the Medicare-care partner into first place ahead of November 4 earnings. Its Springfield Clinic expansion targets roughly 21,000 additional traditional Medicare beneficiaries. Risk: Agilon bears patients’ medical costs under full-risk contracts, leaving profitability exposed to higher care spending.

$INTC ( ▼ 28.58% ) : Intel, S&P 500 #6 → #19: Shares lost -28.6% for the week after Thursday’s earnings. MarketWatch reported weakening PC demand alongside server demand Intel cannot fully satisfy. Risk: Wafer and packaging constraints limit its ability to offset the PC slowdown with AI-server sales.

Next week’s swing factor: ImmunityBio’s November 3 and agilon’s November 4 earnings will test whether healthcare’s rank gains have operating support.

Want to see some change? Respond to this email and reach me, Kevin Travers, with feedback. Follow me on Stocktwits. Send me charts and ideas! Refer a friend for this quarter’s edition of The RIP Forecast 😎

Securities Disclaimer: STOCKTWITS IS NOT A TAX ADVISOR, BROKER, FINANCIAL ADVISOR OR INVESTMENT ADVISOR. THE SERVICE IS NOT INTENDED TO PROVIDE TAX, LEGAL, FINANCIAL OR INVESTMENT ADVICE, AND NOTHING ON THE SERVICE SHOULD BE CONSTRUED AS AN OFFER TO SELL, A SOLICITATION OF AN OFFER TO BUY, OR A RECOMMENDATION FOR ANY SECURITY. Trading in such securities can result in immediate and substantial losses of the capital invested. You should only invest risk capital, and not capital required for other purposes. You alone are solely responsible for determining whether any investment, security or strategy, or any other product or service, is appropriate or suitable for you based on your investment objectives and personal and financial situation. You should also consult an attorney or tax professional regarding your specific legal or tax situation. The Content is to be used for informational and entertainment purposes only and the Service does not provide investment advice for any individual. Stocktwits, its affiliates and partners specifically disclaim any and all liability or loss arising out of any action taken in reliance on Content, including but not limited to market value or other loss on the sale or purchase of any company, property, product, service, security, instrument, or any other matter. You understand that an investment in any security is subject to a number of risks, and that discussions of any security published on the Service will not contain a list or description of relevant risk factors. In addition, please note that some of the stocks about which Content is published on the Service have a low market capitalization and/or insufficient public float. Such stocks are subject to more risk than stocks of larger companies, including greater volatility, lower liquidity and less publicly available information. Read the full terms & conditions here. 🔍

Author Disclosure: The author of this newsletter does not hold positions in any of the securities or assets mentioned. 📋